<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591486</url>
  </required_header>
  <id_info>
    <org_study_id>2NA3NANC</org_study_id>
    <nct_id>NCT01591486</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding</brief_title>
  <acronym>2NA3NANC</acronym>
  <official_title>A Long-term Prospective Cohort Study of Testing for Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding With Low-dose Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low-dose aspirin (ASA) has emerged as the most important cause of peptic ulcer bleeding
      worldwide. In western countries, ASA has overtaken non steroidal antiinflammatory drugs
      (NSAIDs) as a major cause of peptic ulcer bleeding in the elderly population [1,2].
      Management of peptic ulcer bleeding in patients receiving ASA for cardiothrombotic diseases
      is a clinical dilemma. In a randomized trial of continuous versus interrupted ASA therapy
      after endoscopic treatment of peptic ulcer bleeding, patients who discontinued ASA had a
      10-fold increased incidence of all-cause mortality compared to those who received continuous
      ASA therapy. On the other hand, patients receiving continuous ASA therapy had a two-fold
      increased risk of early rebleeding [3]. Thus, preventing the occurrence of peptic ulcer
      bleeding in ASA users is important in reducing morbidity and mortality.

      Given the uncertain clinical utility of Helicobacter Pylori (Hp) testing in ASA users, this
      prospective cohort study aims to determine whether testing for Hp will have any impact on the
      long-term incidence of ulcer bleeding in ASA users with high ulcer risk. The investigators
      hypothesize that among ASA users with Hp infection and ulcer bleeding, the long-term
      incidence of recurrent ulcer bleeding with ASA use will be low after eradication of Hp alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low-dose aspirin (ASA) has emerged as the most important cause of peptic ulcer bleeding
      worldwide. In western countries, ASA has overtaken NSAIDs as a major cause of peptic ulcer
      bleeding in the elderly population [1,2]. Management of peptic ulcer bleeding in patients
      receiving ASA for cardiothrombotic diseases is a clinical dilemma. In a randomized trial of
      continuous versus interrupted ASA therapy after endoscopic treatment of peptic ulcer
      bleeding, patients who discontinued ASA had a 10-fold increased incidence of all-cause
      mortality compared to those who received continuous ASA therapy. On the other hand, patients
      receiving continuous ASA therapy had a two-fold increased risk of early rebleeding [3]. Thus,
      preventing the occurrence of peptic ulcer bleeding in ASA users is important in reducing
      morbidity and mortality.

      Emerging evidence from secondary analysis of cardiovascular trials suggests that aspirin also
      reduces the risk of all cancers, even at cardioprotective doses [4]. With increasing use of
      ASA for cardiothrombotic diseases and cancer prevention, the global burden of ASA-associated
      peptic ulcer disease is expected to increase.

      A number of risk factors are known to increase the risk of peptic ulcer bleeding with ASA
      use. These include a history of peptic ulcer or ulcer bleeding, old age, renal failure,
      concurrent use of ASA and clopidogrel, and Helicobacter pylori (Hp) infection [5-7]. Among
      these risk factors, concomitant use of clopidogrel and a history of peptic ulcer bleeding and
      are important predictors of ulcer bleeding with ASA use [7]. On the other hand, Hp is the
      only risk factor that can be modified. Eradication of Hp therefore offers a hope of reducing
      the risk of ulcer bleeding in ASA users.

      Current European and U.S. guidelines unanimously recommend test-and-treat Hp infection in ASA
      users who are at risk of ulcer bleeding [8-10]. Despite these guidelines, the long-term
      benefit of eradicating Hp in high-risk ASA users is uncertain.

      In a 6-month randomized trial of ASA users with Hp infection complicated by ulcer bleeding,
      patients were randomized to one-week of Hp eradication therapy alone or maintenance treatment
      with omeprazole after ulcers has healed. Our results showed that the incidence of recurrent
      ulcer bleeding was comparable between the group receiving Hp eradication alone (1.9%) and the
      group receiving omeprazole (0.9%) [11]. In another 12-month randomized trial, ASA users with
      Hp infection complicated by ulcer bleeding were randomized to one-week of eradication therapy
      alone or one week of eradication therapy plus maintenance treatment with lansoprazole. In
      this study, up to 15% of ASA users developed recurrent ulcer bleeding after eradication of Hp
      alone. Among the ASA users who developed recurrent ulcer bleeding, however, over two-thirds
      had failure Hp eradication or used concomitant NSAIDs [12].

      In light of these conflicting findings, current guidelines recommend that co-therapy with a
      proton-pump inhibitor (PPI) is still needed in high-risk ASA users after eradication of Hp
      [8-10]. Since PPIs are more effective in preventing ASA-associated ulcers in the presence of
      Hp infection [13], the clinical relevance of testing for Hp in high-risk ASA users becomes
      even more questionable. To date, the strategy of test-and-treat Hp for ASA users is not
      popular among primary care doctors or specialists.

      One alternative gastroprotective strategy is to prescribe PPIs to all ASA users at high risk
      of ulcer bleeding and ignore Hp testing. However, poor compliance to gastroprotective
      co-therapy limits its effectiveness. Recently, health authorities issued warning about the
      the use of PPI and the risk of hip fractures and potential adverse drug-interactions between
      PPI and clopidogrel [14,15]. Clopidgorel is commonly used in combination with ASA for
      preventing coronary stent thrombosis but dual anti-platelet therapy will substantially
      increase the risk of ulcer bleeding [5]. If eradication of Hp can reduce the long-term risk
      of ulcer bleeding with ASA use, there may be a potential hope of limiting PPI use to very
      high risk ASA users.

      Given the uncertain clinical utility of Hp testing in ASA users, this prospective cohort
      study aims to determine whether testing for Hp will have any impact on the long-term
      incidence of ulcer bleeding in ASA users with high ulcer risk. The investigators hypothesize
      that among ASA users with Hp infection and ulcer bleeding, the long-term incidence of
      recurrent ulcer bleeding with ASA use will be low after eradication of Hp alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1995</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The cumulative incidence of gastroduodenal ulcer bleeding</measure>
    <time_frame>10 years</time_frame>
    <description>The cumulative incidence of gastroduodenal ulcer bleeding with ASA use in 10 years. Gastroduodenal ulcer bleeding is defined as haematemesis and/or melaena with gastroduodenal ulcers, or erosions with blood in the stomach confirmed by endoscopy, or a decrease in the haemoglobin level &gt;2 g/dL in the presence of endoscopically proven ulcers.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">904</enrollment>
  <condition>Bacterial Infection Due to Helicobacter Pylori (H. Pylori)</condition>
  <condition>Peptic Ulcer Bleeding</condition>
  <arm_group>
    <arm_group_label>Hp-negative cohort</arm_group_label>
    <description>Hp-negative cohort
The second cohort consists of ASA users with ulcer bleeding but no current or past Hp infection, as evidenced by:
negative rapid urease test
negative histology for Hp infection on both initial and follow-up endoscopy
negative serology test
absence of intestinal metaplasia and atrophy on 4 random biopsies of the antrum and corpus
After ulcer healing, the Hp-negative cohort will receive enteric-coated ASA (&lt;160 mg daily) without regular co-prescription of anti-ulcer drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hp-eradicated cohort</arm_group_label>
    <description>Hp-eradicated cohort This cohort consists of ASA users with ulcer bleeding and Hp infection who have healed ulcers and successful eradication of Hp on follow-up endoscopy. They will receive plain ASA (&lt;160 mg daily) without co-prescription of anti-ulcer drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Average-risk cohort</arm_group_label>
    <description>Average-risk cohort The third cohort consists of ASA-naive patients without a history of ulcer who attend the general outpatient clinic. They require long-term ASA for established cardiothrombotic diseases. They receive plain ASA (&lt;160 mg daily) without co-prescription of anti-ulcer drugs. Hp status will not be determined in this cohort because Hp testing is not justified in average-risk asymptomatic patients.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive users of ASA presented with upper gastrointestinal bleeding to the Endoscopy
        Centre of the Prince of Wales Hospital will be screened for eligibility. The Prince of
        Wales Hospital serves a local population of 1.5 million people in Hong Kong. All patients
        undergo endoscopy within 24 hours of hospitalisation to identify the source of bleeding, to
        secure haemostasis, and to determine their Hp status.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gastroduodenal ulcer bleeding confirmed by endoscopy

          2. Anticipated regular use of ASA for cardiothrombotic diseases

        Exclusion Criteria:

          1. Uncontrolled bleeding requiring surgical intervention

          2. Previous gastric surgery except for a patch repair

          3. Gastroesophageal varices

          4. Gastric-outlet obstruction

          5. Gastroesophageal reflux disease requiring regular acid suppressive therapy

          6. Renal failure (defined by a serum creatinine level of more than 200 Î¼mol per liter)

          7. Moribund conditions

          8. Active malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis KL CHAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endoscopy Center, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong (SAR)</city>
        <zip>852</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Francis KL Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori (Hp)</keyword>
  <keyword>ASA users</keyword>
  <keyword>peptic ulcer bleeding</keyword>
  <keyword>cohorts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Peptic Ulcer Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

